Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Previous studies in high-fat diet-induced AD animal models have shown that brain insulin resistance in these animals leads to the accumulation of amyloid beta (Aβ) and the reduction in GSK-3β phosphorylation, which promotes tau phosphorylation to cause AD.
|
27810390 |
2017 |
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our findings further support that increased kinase activity of GSK3β is associated with AD pathology in the PFC.
|
29804228 |
2019 |
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, VPA treatment increased β-catenin levels, accumulated the inactive form of glycogen synthase kinase-3β (GSK-3β), and induced the expression of NeuroD1, a Wnt target gene involved in neurogenesis, suggesting the activation of the Wnt signaling pathway in the hippocampus of 3xTgAD mice.
|
30971911 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Tau, a microtubule-associated protein and substrate for GSK3β, has been implicated in the pathogenesis of tauopathies such as Alzheimer's disease.
|
22922102 |
2012 |
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
However, whether the inhibition of the activation of mTOR via the regulation of the function of GSK3β affects the pathology of AD remains unclear.
|
31115485 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Findings were further validated by expression analyses of a target gene GSK3B, known to be affected by AD and PD.
|
27853238 |
2016 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
LHGDN |
Intracellular domains of amyloid precursor-like protein 2 interact with CP2 transcription factor in the nucleus and induce glycogen synthase kinase-3beta expression.
|
16645641 |
2007 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Glycogen synthase kinase-3β (GSK-3β), a serine/threonine kinase also known as tau protein kinase I, has been implicated in the pathogenic conditions of Alzheimer's disease.
|
21561378 |
2011 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
In experiments with cultured HEK293T cells, we show here that GSK3β stabilizes synaptic acetylcholinesterase (AChE-S), a critical component of AD development.
|
22944069 |
2013 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Herein, we highlight nine major targets associated with AD, which are acetylcholine esterase (AChE), beta-site amyloid precursor protein cleaving enzyme 1 (β-secretase, BACE-1), glycogen synthase kinase 3 beta (GSK-3β), monoamine oxidases (MAOs), metal ions in the brain, N-methyl-D-aspartate (NMDA) receptor, 5-hydroxytryptamine (5-HT) receptors, the third subtype of histamine receptor (H<sub>3</sub> receptor), and phosphodiesterases (PDEs), and their respective relationship to the disease network.
|
31103902 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease.
|
26171616 |
2015 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The new inhibitors are valuable chemical probes and drug leads with therapeutic potential to tackle AD and other GSK-3β relevant diseases.
|
29381861 |
2018 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The prolyl isomerase Pin1 and glycogen synthase kinase-3β (GSK3β) have been shown to have the opposite effects on APP processing and Tau hyperphosphorylation, relevant to the pathogenesis of AD.
|
22184106 |
2012 |
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In AD patients, the mRNA expression level of the GSK-3β gene is increased and may be related to age and behavioural pathology in AD.
|
23279147 |
2012 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3β as targets for Alzheimer's disease.
|
28950235 |
2017 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
For this reason, other biochemical pathways associated with the pathophysiology of AD have been explored as alternatives to the treatment of this condition such as inhibition of β-secretase and glycogen synthase kinase-3β.
|
30191777 |
2018 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Thus, our previous and present findings raise the unifying prospect that Aβ•CaSR signaling plays a crucial role in AD development and progression by simultaneously activating (i) the amyloidogenic processing of amyloid precursor holoprotein, whose upshot is a surplus production and secretion of Aβ<sub>42</sub> oligomers, and (ii) the GSK-3β-mediated increased production of p-Tau oligomers which are next released extracellularly inside exosomes.
|
28473749 |
2017 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this sense, here we report the rational design of a multi-target directed ligand (MTDL) for AD based on virtual screening and bioinformatic analyses, exploring the molecular targets β-secretase (BACE-1), glycogen synthase kinase-3β (GSK-3β) and acetylcholinesterase (AChE).
|
31086208 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review.
|
29332582 |
2017 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
CTD_human |
Lithium treatment induces proteasomal degradation of over-expressed acetylcholinesterase (AChE-S) and inhibit GSK3β.
|
22944069 |
2013 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The quinolin-2-one derivative ZINC67773573 was found to be a promising lead for designing new GSK-3β inhibitors for Alzheimer's disease treatment.
|
31129879 |
2019 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This work aims to provide a novel tool for early diagnosis and pathological mechanism exploration about AD by detecting inchoate change of GSK-3β content in body fluid, thus to precaution the risk of Alzheimer's disease.
|
31322849 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Leptin may be protective against the development of AD as it can inactivate GSK-3β through the phosphorylation of Ser-9, leading to the reduction of tau phosphorylation.
|
30954605 |
2019 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The association between single nucleotide polymorphisms of GSK 3β gene and sporadic Alzheimer's disease in a cohort of southern Chinese Han population.
|
25141968 |
2014 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Arylbenzofurans from the Root Bark of <i>Morus alba</i> as Triple Inhibitors of Cholinesterase, β-Site Amyloid Precursor Protein Cleaving Enzyme 1, and Glycogen Synthase Kinase-3β: Relevance to Alzheimer's Disease.
|
31459768 |
2019 |